Rate My Professor Julian Gillmore

Professor Julian Gillmore is Professor of Medicine in the Division of Medicine at University College London (UCL). He serves as Head of the UCL Centre for Amyloidosis and Acute Phase Proteins since 2019 and Research Lead at the UK National Amyloidosis Centre (NAC), both based at the Royal Free Hospital. As Honorary Consultant Nephrologist at Royal Free London NHS Foundation Trust, he qualified with MBBS, MD from Imperial College London in 2001, PhD from UCL in 2004, and FRCP. His MD and PhD research focused on serum amyloid P component, antinuclear autoimmunity, characterisation, and treatment of hereditary and acquired systemic amyloidosis. He trained in renal medicine at the Royal Free Hospital and has held consultant positions there.

Gillmore's clinical research centres on the pathogenesis, diagnosis, treatment, and prognosis of systemic amyloidosis, particularly hereditary transthyretin (ATTR) amyloidosis, AL amyloidosis, and cardiac amyloidosis. He led the first-in-human in vivo CRISPR-Cas9 gene editing trial for transthyretin amyloidosis, published in the New England Journal of Medicine (2021), demonstrating durable reduction in serum transthyretin and halting disease progression. Key publications include 'Nonbiopsy diagnosis of cardiac transthyretin amyloidosis' (2016, over 2,300 citations), 'Systemic amyloidosis' (2016), 'Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group' (2021), and 'Natural history and outcome in systemic AA amyloidosis' (2007). With over 250 peer-reviewed articles cited tens of thousands of times, he has supervised numerous postgraduate MD and PhD students. His contributions include developing a UK haematologist network for AL amyloidosis, leading the first randomised controlled trial for AL amyloidosis with the UK Myeloma Forum, co-founding a patient support group, authoring the British Guidelines on AL Amyloidosis management (2013), and pioneering links between amyloid fibril precursor protein abundance and clinical outcomes in a 2001 Lancet paper. Recent work shows potential for reversing cardiac amyloidosis through novel therapies.